Biotechnology

Effects of deferoxamine and ferrostatin-1 on salivary gland dysfunction in


“(…) this research is expected to assist in (…) developing a treatment for postmenopausal dry mouth.”

Credit: 2023 Cheon et al.

“(…) this research is expected to assist in (…) developing a treatment for postmenopausal dry mouth.”

BUFFALO, NY- April 262023 – A new research paper is published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 15, Issue 7entitled, “Effects of deferoxamine and ferrostatin-1 on salivary gland dysfunction in ovariectomized rats.”

Xerostomia can be defined as a subjective sensation associated with reduced lubrication and dehydration of the oral mucosa. Xerostomia is known to be common in the elderly, especially women, and its prevalence has been estimated to range from 5.5% to 46%. The mechanisms underlying xerostomia after menopause have not been fully elucidated.

In this new study, the researchers Yong-Il Cheon, Ji Min Kim, Sung-Chan Shin, Hyung-Sik Kim, Jin-Choon Lee, Gi Cheol Park, Eui-Suk Sung, Minhyung Lee, And Byung-Joo Lee from Pusan ​​National University And Sungkyunkwan University School of Medicine aimed to investigate the mechanism of xerostomia and the effects of the ferroptosis inhibitors deferoxamine (DFO) and ferrostatin-1 (FER) on salivary gland dysfunction in a postmenopausal animal model.

“It was recently reported that ferroptosis in the salivary glands may be associated with xerostomia that occurs after menopause (30). However, to date there have been no studies using anti-ferroptosis drugs to investigate the mechanisms underlying postmenopausal salivary gland dysfunction.”

Twenty-four female Sprague-Dawley mice were randomly divided into four groups: SHAM group (n = 6, sham-operated mice), OVX group (n = 6, ovariectomized mice), FER group (n = 6, ovariectomized mice). injected intraperitoneally with FER), and the DFO group (n = 6, ovariectomized mice injected intraperitoneally with DFO). GPX4 activity, iron accumulation, lipid peroxidation, inflammation, fibrosis and salivary gland function were analyzed.

Recovery of GPX4 activity and decreased accumulation of cytosolic iron and MDA + HAE were observed in the DFO group. In addition, the levels of collagen I, collagen III, TGF-β, IL-6, TNF-α, and TGF-β decreased in the DFO group compared to the OVX group. Restoration of GPX4 activity and mitochondrial morphology, and reduction of cytosolic MDA + HAE were also observed in the FER group. In addition, decreased expression of inflammatory cytokines and fibrosis markers as well as increased AQP5 expression were observed in the DFO and FER groups.

Postmenopausal salivary gland dysfunction is associated with ferroptosis. This is the first study to investigate the effect of ferroptosis inhibitors (DFO and FER) on the salivary glands of ovariectomized rats. DFO and FER are considered promising treatments for postmenopausal xerostomia.

“In the absence of a standard treatment for postmenopausal dry mouth, it is hoped that this research will assist in understanding the mechanisms of postmenopausal salivary gland dysfunction and developing treatments for postmenopausal dry mouth.”

Read the full study: DOI: https://doi.org/10.18632/aging.204641

Corresponding author: Byung-Joo Lee

Appropriate e-mail: (email protected)

Keywords: menopause, ferroptosis, xerostomia, deferoxamine, ferrostatin-1

Sign up for free Altmetric alerts about this article: https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204641

About Aging-US:

Launched in 2009, Aging published papers of general interest and biological significance in all areas of research on aging and age-related diseases, including cancer—and now, with a particular focus on COVID-19 susceptibility as an age-dependent syndrome. topic in Aging goes beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g. p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at www.Aging-US.comand connect with us:

  • SoundCloud
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LabTube
  • LinkedIn
  • Reddit
  • Pinterest

Click here to subscribe to Aging publication updates.

For media inquiries, please contact (email protected).

Aging Journal Office (Aging-US).

6666 E. Quaker Str., Suite 1B

Orchard Park, New York 14127

Phone: 1-800-922-0957, option 1

###






Source link

Related Articles

Back to top button